{"id":2076,"date":"2026-06-21T07:33:16","date_gmt":"2026-06-21T07:33:16","guid":{"rendered":"https:\/\/one-peptides.com\/?p=2076"},"modified":"2026-10-03T14:55:57","modified_gmt":"2026-10-03T14:55:57","slug":"cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says","status":"publish","type":"post","link":"https:\/\/one-peptides.com\/de\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\/","title":{"rendered":"CJC-1295 (DAC and No DAC) \u2014 the difference between the variants and what the research says"},"content":{"rendered":"<div class=\"op-breadcrumbs\" style=\"margin:0 0 18px;font-size:13px;color:#6b7280;\"><div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t<a href=\"https:\/\/one-peptides.com\/de\/\" title=\"Home\">Home<\/a>\n<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t<a href=\"https:\/\/one-peptides.com\/de\/category\/regeneration\/\" title=\"Regeneration &amp; research peptides\">Regeneration &amp; research peptides<\/a>\n<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\tCJC-1295 (DAC and No DAC) \u2014 the difference between the variants and what the research says\n<\/span><\/div><\/div>\n<p>In the research-reagent trade, the name &#8220;CJC-1295&#8221; covers <strong>two distinct variants<\/strong> of the same peptide \u2014 differing by a single chemical modification that changes the half-life by two orders of magnitude. The DAC variant and the no-DAC variant are frequently confused, yet the difference between them is fundamental for anyone evaluating a reagent for the reproducibility of an experimental protocol. The certificate of analysis (COA) \u2014 sequence and molecular weight \u2014 is the only binding signal that distinguishes them; the trade name alone is not sufficient.<\/p>\n<p><strong>CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), occurring in two variants: with DAC (Drug Affinity Complex \u2014 long half-life, around 6\u20138 days) and without DAC (known as Mod GRF 1-29 \u2014 short half-life, around 30 minutes). Both are studied as stimulators of the growth hormone axis, but their pharmacokinetic profile differs radically. A chemical reagent intended for laboratory research (Research Use Only).<\/strong><\/p>\n<blockquote><p>The following article is educational in nature and constitutes a review of the published scientific literature. All One Peptides products in the lyophilised peptides category are chemical reagents intended exclusively for laboratory research (Research Use Only). They are not medicinal products, dietary supplements or foodstuffs.<\/p><\/blockquote>\n<h2>Table of contents<\/h2>\n<ul>\n<li><a href=\"#czym-jest\">What CJC-1295 is \u2014 a GHRH analogue<\/a><\/li>\n<li><a href=\"#dac-vs-bez-dac\">DAC vs no DAC \u2014 the fundamental difference<\/a><\/li>\n<li><a href=\"#mechanizm\">Mechanism \u2014 pulsatile vs continuous GH release<\/a><\/li>\n<li><a href=\"#badania\">What the research says<\/a><\/li>\n<li><a href=\"#synergia\">CJC-1295 + Ipamorelin \u2014 synergy in research<\/a><\/li>\n<li><a href=\"#coa\">How to read a COA<\/a><\/li>\n<li><a href=\"#faq\">Frequently asked questions<\/a><\/li>\n<\/ul>\n<h2>What CJC-1295 is \u2014 a GHRH analogue<\/h2>\n<p>CJC-1295 is a synthetic <strong>analogue of growth hormone-releasing hormone (GHRH)<\/strong> \u2014 a peptide produced by the hypothalamus that stimulates the pituitary to secrete growth hormone (GH). The molecule is based on the GHRH(1-29) fragment \u2014 the first 29 amino acids of natural GHRH, which constitute the minimal region retaining the hormone&#8217;s full biological activity.<\/p>\n<p>Natural GHRH has a very short half-life \u2014 on the order of a few minutes \u2014 owing to rapid degradation by the enzyme dipeptidyl peptidase IV (DPP-4) and other plasma peptidases. CJC-1295 introduces <strong>stabilising modifications<\/strong> to the GHRH(1-29) sequence against this degradation: four amino acid substitutions (tetrasubstitution) protecting against proteolysis. It is on this shared core that both variants are built \u2014 the difference comes down to the presence or absence of an additional structural element called DAC.<\/p>\n<h2>DAC vs no DAC \u2014 the fundamental difference<\/h2>\n<p>This is the crux of the distinction. Both variants share the same GHRH(1-29) core with stabilising substitutions, but they differ in the presence of the <strong>Drug Affinity Complex (DAC)<\/strong> \u2014 a chemical moiety that drastically alters the pharmacokinetics.<\/p>\n<table style=\"min-width: 75px; border-collapse: collapse; border-spacing: 0px; width: 100%;\" data-border-width=\"1\">\n<thead>\n<tr>\n<th style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Feature<\/th>\n<th style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">CJC-1295 with DAC<\/th>\n<th style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">CJC-1295 without DAC (Mod GRF 1-29)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Additional modification<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Maleimide moiety (DAC)<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">None \u2014 stabilising tetrasubstitution only<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Albumin binding<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Covalent, permanent<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">None<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Half-life<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">~6\u20138 days<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">~30 minutes<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">GH release profile<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Continuous, prolonged elevation (the &#8220;bleed&#8221;)<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Pulsatile, short peaks<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Molecular weight<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Higher (with the DAC moiety)<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Lower<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Alternative trade name<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">CJC-1295 DAC<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Mod GRF 1-29, CJC-1295 no DAC<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>DAC (Drug Affinity Complex)<\/strong> is a maleimide moiety attached to the peptide which, once introduced into the system, <strong>binds covalently to serum albumin<\/strong> \u2014 the most abundant plasma protein. Albumin binding functions as a reservoir: it protects the peptide from degradation and renal excretion, extending the half-life from minutes to days. The DAC variant therefore has a half-life on the order of <strong>6\u20138 days<\/strong>.<\/p>\n<p><strong>The no-DAC variant<\/strong> \u2014 widely known in the trade as <strong>Mod GRF 1-29<\/strong> (modified GRF 1-29) \u2014 has no maleimide moiety. It possesses only the tetrasubstitution protecting against DPP-4, which yields a half-life on the order of <strong>30 minutes<\/strong>. Without albumin binding, the molecule is cleared rapidly.<\/p>\n<p>The difference in molecular weight resulting from the presence of the DAC moiety is visible in mass spectrometry \u2014 it is one of the binding signals for distinguishing the two variants at the analytical level.<\/p>\n<h2>Mechanism \u2014 pulsatile vs continuous GH release<\/h2>\n<p>Both CJC-1295 variants bind the <strong>GHRH receptor (GHRHR)<\/strong> on pituitary somatotroph cells, stimulating growth hormone secretion. The difference in half-life, however, translates into a fundamentally different <strong>temporal pattern<\/strong> of GH release \u2014 which has significant research implications.<\/p>\n<p><strong>The no-DAC variant (Mod GRF 1-29)<\/strong> \u2014 with its short half-life \u2014 produces a <strong>pulsatile<\/strong> pattern of stimulation. A short peak of peptide activity elicits a short burst of GH, after which the hormone level returns to baseline. This pattern is closer to the physiological rhythm of GH secretion, which in a healthy organism occurs in pulses \u2014 mainly nocturnal.<\/p>\n<p><strong>The DAC variant<\/strong> \u2014 with a half-life measured in days \u2014 maintains a <strong>continuous, prolonged elevation<\/strong> of GH and IGF-1 levels. In the literature this phenomenon is sometimes termed the &#8220;bleed&#8221; \u2014 a steady, low background of GHRH activity instead of distinct pulses. The research implications of this continuous profile differ from those of the pulsatile profile \u2014 among other things, in the context of receptor sensitivity and feedback within the GH axis.<\/p>\n<p>For a researcher designing an experiment on the growth hormone axis, the distinction matters: the no-DAC variant models pulsatile stimulation, the DAC variant continuous exposure. These are two different experimental systems.<\/p>\n<h2>What the research says<\/h2>\n<p>CJC-1295 has been the subject of pharmacokinetic and pharmacodynamic studies, mainly in the context of its effect on GH and IGF-1 levels in healthy volunteers. The table below summarises the main areas of research.<\/p>\n<table style=\"min-width: 75px; border-collapse: collapse; border-spacing: 0px; width: 100%;\" data-border-width=\"1\">\n<thead>\n<tr>\n<th style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Research area<\/th>\n<th style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Model<\/th>\n<th style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">What was observed<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Pharmacokinetics of the DAC variant<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Human studies (healthy volunteers)<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Prolonged elevation of GH\/IGF-1, half-life measured in days<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Effect on GH secretion<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Human studies<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Increase in serum GH and IGF-1 concentrations<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">GHRH(1-29) profile and stabilisation<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Preclinical and analytical studies<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Resistance to DPP-4 thanks to tetrasubstitution<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The literature on CJC-1295 encompasses pharmacokinetic work on the DAC variant as well as studies on GHRH(1-29) and its analogues. Full identification of the sources can be found in the bibliography at the end of the article.<\/p>\n<h2>CJC-1295 + Ipamorelin \u2014 synergy in research<\/h2>\n<p>In the research literature and in laboratory protocols, CJC-1295 (a GHRH analogue) is sometimes combined with <strong><a href=\"\/product\/ipamorelin-2mg\/\">Ipamorelin<\/a><\/strong> \u2014 a selective agonist of the growth hormone secretagogue receptor (GHS-R). The basis for this pairing is the complementarity of the mechanisms: CJC-1295 acts through the GHRH receptor, Ipamorelin through the distinct GHS-R receptor. Activating two different receptors of the GH axis simultaneously produces, in research, a stronger effect than activating either one alone \u2014 two independent pathways of somatotroph stimulation.<\/p>\n<p>The selectivity of Ipamorelin \u2014 releasing GH without a significant effect on cortisol and prolactin \u2014 makes it a frequent partner of CJC-1295 in research protocols on the growth hormone axis. The mechanism and profile of Ipamorelin are described in detail in <a href=\"https:\/\/one-peptides.com\/ipamorelin-a-selective-growth-hormone-secretagogue-what-the-research-says\/\">a separate article devoted to that peptide<\/a>.<\/p>\n<h2>How to read a COA<\/h2>\n<p>Distinguishing the DAC variant from the no-DAC variant rests on two fields of the certificate of analysis:<\/p>\n<ul>\n<li><strong>Amino acid sequence<\/strong> \u2014 both variants have the GHRH(1-29) core with tetrasubstitution; the DAC variant additionally has a maleimide moiety (DAC) attached, which is indicated in the structure description<\/li>\n<li><strong>Molecular weight measured by MS<\/strong> \u2014 the presence of the DAC moiety raises the molecular weight; the difference is visible in mass spectrometry and unambiguously distinguishes the two variants<\/li>\n<\/ul>\n<p>The trade name alone does not identify the variant unambiguously \u2014 &#8220;CJC-1295&#8221; without the qualifier &#8220;DAC&#8221; or &#8220;no DAC \/ Mod GRF 1-29&#8221; is insufficient. If a COA does not include the sequence and molecular weight, require the supplier to supply them. A full description of the quality control procedure can be found in the section on <a href=\"\/quality-testing-and-certificates\/\">quality testing and certificates<\/a>.<\/p>\n<h2>Safety and limitations<\/h2>\n<p>CJC-1295 remains a research reagent without medicinal status. Its safety profile is known solely from limited pharmacokinetic studies on the GH axis \u2014 there are no long-term data on chronic exposure in humans. The continuous profile of the DAC variant (prolonged elevation of GH\/IGF-1) differs from the physiological pulsatile pattern, which the literature indicates as an area requiring further research with respect to feedback within the somatotrophic axis.<\/p>\n<p>GHRH analogues and growth hormone secretagogues are on the WADA list of prohibited substances (category S2 \u2014 peptide hormones, growth factors and secretagogues). Athletes subject to anti-doping control should verify the current status before any use.<\/p>\n<h2>CJC-1295 as a research reagent<\/h2>\n<p>In the One Peptides catalogue, both CJC-1295 variants \u2014 <strong><a href=\"\/product\/cjc-1295-with-dac-5mg\/\">with DAC<\/a><\/strong> and <strong><a href=\"\/product\/cjc-w-o-dac-5mg\/\">without DAC<\/a><\/strong> \u2014 are available as separate RUO research-reagent SKUs. Every batch of each variant undergoes five-stage analytical control: HPLC \u226598% (chromatographic purity), MS confirmation (structural identity confirming the presence or absence of the DAC moiety), COA per batch, cold chain 2\u20138\u00b0C and batch traceability. The certificate of analysis with the molecular weight is the document that distinguishes the two variants \u2014 it is its MS field that allows the DAC variant to be told apart from Mod GRF 1-29 unambiguously.<\/p>\n<h2>Frequently asked questions<\/h2>\n<p><strong>CJC-1295 DAC vs no DAC \u2014 what is the difference?<\/strong><br \/>\nBoth variants have the same GHRH(1-29) analogue core, but the DAC variant additionally has a maleimide moiety (Drug Affinity Complex), which binds covalently to serum albumin and extends the half-life from around 30 minutes (the no-DAC variant) to around 6\u20138 days (the DAC variant). The no-DAC variant produces a pulsatile GH release profile, the DAC variant a continuous prolonged elevation. The molecular weight in the COA distinguishes the two variants.<\/p>\n<p><strong>What is DAC?<\/strong><br \/>\nDAC (Drug Affinity Complex) is a maleimide moiety attached to the CJC-1295 peptide. Once introduced into the system, it binds covalently to serum albumin \u2014 the most abundant plasma protein \u2014 which protects the peptide from degradation and extends the half-life from minutes to days. It is a technology that prolongs the peptide&#8217;s action by using albumin as a reservoir.<\/p>\n<p><strong>What is Mod GRF 1-29?<\/strong><br \/>\nMod GRF 1-29 (modified GRF 1-29) is another name for the no-DAC variant of CJC-1295. &#8220;GRF&#8221; is the abbreviation for growth hormone-releasing factor (a synonym for GHRH), &#8220;1-29&#8221; denotes the fragment of the first 29 amino acids, and &#8220;modified&#8221; indicates the tetrasubstitution stabilising it against DPP-4. It is a peptide with a short half-life (~30 minutes) and a pulsatile GH release profile.<\/p>\n<p><strong>CJC-1295 with Ipamorelin \u2014 why this combination?<\/strong><br \/>\nCJC-1295 (a GHRH analogue) and Ipamorelin (a GHS-R agonist) act through two different receptors of the growth hormone axis. In research, simultaneous activation of both receptors produces a stronger effect on GH secretion than activation of either one alone \u2014 these are complementary mechanisms. The selectivity of Ipamorelin (no significant effect on cortisol and prolactin) makes it a frequent partner of CJC-1295 in research protocols.<\/p>\n<p><strong>Is CJC-1295 on the WADA list?<\/strong><br \/>\nYes. GHRH analogues and growth hormone secretagogues are on the WADA list of prohibited substances under category S2 (peptide hormones, growth factors and related substances). The prohibition applies all year round. Athletes subject to anti-doping control may not use CJC-1295 at any time.<\/p>\n<h2>Related content in the knowledge base<\/h2>\n<p>CJC-1295 belongs to the growth hormone secretagogue (GHS) group of research peptides. Thematically it links to <strong>Ipamorelin<\/strong> (a selective GHS-R agonist, a frequent partner in protocols), <strong><a href=\"\/ghrp-2-vs-ghrp-6-differences-pralmorelin-and-what-the-research-says\/\">GHRP-2<\/a> and <a href=\"\/ghrp-2-vs-ghrp-6-differences-pralmorelin-and-what-the-research-says\/\">GHRP-6<\/a><\/strong> (classic peptides that release GH through the ghrelin receptor), <strong><a href=\"\/peg-mgf-pegylated-mechano-growth-factor-what-the-research-says-about-muscle-regeneration\/\">PEG-MGF<\/a><\/strong> (an IGF-1 splice variant with a distinct regenerative mechanism), <strong><a href=\"\/product\/mk-677-ibutamoren-10-mg-60-capsules\/\">MK-677<\/a><\/strong> (an oral GH secretagogue) and <strong><a href=\"\/category-product\/hgh-fragment-176-191\/\">HGH Fragment 176-191<\/a><\/strong> (a growth hormone fragment). Each of these peptides has its own article and product page with a full chemical characterisation.<\/p>\n<h2>Summary<\/h2>\n<p>CJC-1295 is a GHRH analogue available in two variants differing by a single modification \u2014 the presence of the Drug Affinity Complex (DAC). The DAC variant binds covalently to albumin and has a half-life of around 6\u20138 days with a continuous GH release profile. The no-DAC variant (Mod GRF 1-29) has a half-life of around 30 minutes with a pulsatile profile closer to physiology. The difference in molecular weight in the COA is the binding signal that distinguishes the two variants \u2014 the trade name alone is not sufficient.<\/p>\n<p>For a researcher designing an experiment on the growth hormone axis, the choice of variant determines the exposure system: pulsatile (no DAC) or continuous (with DAC). Both remain RUO research reagents, on the WADA prohibited list (S2), without medicinal status.<\/p>\n<blockquote><p><strong>Disclaimer<\/strong><\/p>\n<p>All One Peptides products in the lyophilised peptides category (including both CJC-1295 variants) are chemical reagents intended exclusively for laboratory research (Research Use Only). They are not medicinal products, dietary supplements or foodstuffs. They are not intended for administration to humans or animals outside a controlled experimental environment. CJC-1295 is on the WADA list of prohibited substances (category S2). The information in this article is educational in nature and constitutes a review of the published scientific literature; it does not constitute medical advice or a suggestion of use in humans.<\/p><\/blockquote>\n<h2>Bibliography<\/h2>\n<ol>\n<li>Teichman SL et al. (2006). <a href=\"https:\/\/doi.org\/10.1210\/jc.2005-1536\" target=\"_blank\" rel=\"noopener noreferrer\"><cite>Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GHRH<\/cite><\/a><\/li>\n<li>Ionescu M, Frohman LA (2006). <a href=\"https:\/\/doi.org\/10.1210\/jc.2006-1702\" target=\"_blank\" rel=\"noopener noreferrer\"><cite>Pulsatile secretion of growth hormone induced by a GHRH analog with prolonged half-life<\/cite><\/a><\/li>\n<li>Alba M et al. (2006). <a href=\"https:\/\/doi.org\/10.1152\/ajpendo.00201.2006\" target=\"_blank\" rel=\"noopener noreferrer\"><cite>Once-daily administration of a long-acting GHRH analog stimulates the GH\/IGF-1 axis<\/cite><\/a><\/li>\n<li>Sackmann-Sala L et al. (2009). <a href=\"https:\/\/doi.org\/10.1016\/j.ghir.2009.03.001\" target=\"_blank\" rel=\"noopener noreferrer\"><cite>Activation of the GH\/IGF-1 axis by CJC-1295, a long-acting GHRH analog<\/cite><\/a><\/li>\n<\/ol>\n<p><script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"CJC-1295 DAC vs no DAC \u2014 what is the difference?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Both variants have the same GHRH(1-29) analogue core, but the DAC variant additionally has a maleimide moiety (Drug Affinity Complex), which binds covalently to serum albumin and extends the half-life from around 30 minutes (the no-DAC variant) to around 6\u20138 days (the DAC variant). The no-DAC variant produces a pulsatile GH release profile, the DAC variant a continuous prolonged elevation. The molecular weight in the COA distinguishes the two variants.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is DAC?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"DAC (Drug Affinity Complex) is a maleimide moiety attached to the CJC-1295 peptide. Once introduced into the system, it binds covalently to serum albumin \u2014 the most abundant plasma protein \u2014 which protects the peptide from degradation and extends the half-life from minutes to days. It is a technology that prolongs the peptide's action by using albumin as a reservoir.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is Mod GRF 1-29?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Mod GRF 1-29 (modified GRF 1-29) is another name for the no-DAC variant of CJC-1295. \\\"GRF\\\" is the abbreviation for growth hormone-releasing factor (a synonym for GHRH), \\\"1-29\\\" denotes the fragment of the first 29 amino acids, and \\\"modified\\\" indicates the tetrasubstitution stabilising it against DPP-4. It is a peptide with a short half-life (~30 minutes) and a pulsatile GH release profile.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"CJC-1295 with Ipamorelin \u2014 why this combination?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"CJC-1295 (a GHRH analogue) and Ipamorelin (a GHS-R agonist) act through two different receptors of the growth hormone axis. In research, simultaneous activation of both receptors produces a stronger effect on GH secretion than activation of either one alone \u2014 these are complementary mechanisms. The selectivity of Ipamorelin (no significant effect on cortisol and prolactin) makes it a frequent partner of CJC-1295 in research protocols.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is CJC-1295 on the WADA list?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Yes. GHRH analogues and growth hormone secretagogues are on the WADA list of prohibited substances under category S2 (peptide hormones, growth factors and related substances). The prohibition applies all year round. Athletes subject to anti-doping control may not use CJC-1295 at any time.\"\n      }\n    }\n  ]\n}\n<\/script><\/p>\n<p><!-- onep-post-reviewer-banner:start --><\/p>\n<div class=\"author-box onep-post-reviewer-banner\" style=\"border-left: 4px solid #958e09; background: #f9fafb; padding: 16px 20px; margin: 32px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0; font-size: 14px; line-height: 1.5;\"><strong>Pharmaceutical review:<\/strong> <a href=\"https:\/\/one-peptides.com\/team-aneta-kropicka\/\">MPharm Aneta Kropicka<\/a><br \/>\n<em>Pharmaceutical reviewer and sports supplementation expert.<\/em><br \/>\nMaster of Pharmacy with 12 years of professional experience, graduate of the Medical University of \u0141\u00f3d\u017a (2014). Verifies One Peptides content for pharmacology, clinical dosing, and regulatory compliance across RUO \/ dietary supplement \/ drug frameworks.<\/p>\n<p style=\"margin: 0; font-size: 12px; color: #6b7280;\"><small>Published: <time datetime=\"2026-06-21\">2026-06-21<\/time> \u2022 Last updated: <time datetime=\"2026-06-21\">2026-06-21<\/time><\/small><\/p>\n<\/div>\n<p><!-- onep-post-reviewer-banner:end --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In the research-reagent trade, the name &#8220;CJC-1295&#8221; covers two distinct variants of the same peptide \u2014 differing by a single chemical modification that changes the half-life by two orders of magnitude. The DAC variant and the no-DAC variant are frequently confused, yet the difference between them is fundamental for anyone evaluating a reagent for the [&hellip;]<\/p>\n","protected":false},"author":31,"featured_media":2077,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[149],"tags":[],"class_list":["post-2076","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-regeneration"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO Pro 5.0.3 - aioseo.com -->\n\t<meta name=\"description\" content=\"CJC-1295 with DAC (half-life ~6\u20138 days) vs. without DAC \/ Mod GRF 1-29 (~30 min). Differences between peptides variants, mechanism of action. Research-use-only.\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Bartosz Bartczak\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/one-peptides.com\/de\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\/\" \/>\n\t\t<meta name=\"generator\" content=\"All in One SEO Pro (AIOSEO) 5.0.3\" \/>\n\t\t<meta property=\"og:locale\" content=\"de_DE\" \/>\n\t\t<meta property=\"og:site_name\" content=\"One-Peptides -\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"CJC-1295 DAC vs. Non-DAC \u2014 Differences | One Peptides\" \/>\n\t\t<meta property=\"og:description\" content=\"CJC-1295 with DAC (half-life ~6\u20138 days) vs. without DAC \/ Mod GRF 1-29 (~30 min). Differences between peptides variants, mechanism of action. Research-use-only.\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/one-peptides.com\/de\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/one-peptides.com\/wp-content\/uploads\/2026\/06\/cjc-1295.webp\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/one-peptides.com\/wp-content\/uploads\/2026\/06\/cjc-1295.webp\" \/>\n\t\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-06-21T07:33:16+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-10-03T14:55:57+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"CJC-1295 DAC vs. Non-DAC \u2014 Differences | One Peptides\" \/>\n\t\t<meta name=\"twitter:description\" content=\"CJC-1295 with DAC (half-life ~6\u20138 days) vs. without DAC \/ Mod GRF 1-29 (~30 min). Differences between peptides variants, mechanism of action. Research-use-only.\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/one-peptides.com\/wp-content\/uploads\/2026\/06\/cjc-1295.webp\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\\\/#blogposting\",\"name\":\"CJC-1295 DAC vs. Non-DAC \\u2014 Differences | One Peptides\",\"headline\":\"CJC-1295 (DAC and No DAC) \\u2014 the difference between the variants and what the research says\",\"author\":{\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/team-bartosz-bartczak\\\/#person\"},\"publisher\":{\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/one-peptides.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cjc-1295.webp\",\"width\":1536,\"height\":1024,\"caption\":\"CJC-1295 with DAC vs. without DAC\"},\"datePublished\":\"2026-06-21T07:33:16+00:00\",\"dateModified\":\"2026-10-03T14:55:57+00:00\",\"inLanguage\":\"de-DE\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\\\/#webpage\"},\"articleSection\":\"Regeneration &amp; research peptides\",\"wordCount\":2145,\"reviewedBy\":{\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/team-aneta-kropicka\\\/#person\"}},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/category\\\/regeneration\\\/#listItem\",\"name\":\"Regeneration &amp; research peptides\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/category\\\/regeneration\\\/#listItem\",\"position\":2,\"name\":\"Regeneration &amp; research peptides\",\"item\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/category\\\/regeneration\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\\\/#listItem\",\"name\":\"CJC-1295 (DAC and No DAC) \\u2014 the difference between the variants and what the research says\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\\\/#listItem\",\"position\":3,\"name\":\"CJC-1295 (DAC and No DAC) \\u2014 the difference between the variants and what the research says\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/category\\\/regeneration\\\/#listItem\",\"name\":\"Regeneration &amp; research peptides\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/#organization\",\"name\":\"One-Peptides\",\"url\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/one-peptides.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/cropped-Image-1-e1751599136894.png\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\\\/#organizationLogo\",\"width\":291,\"height\":113},\"image\":{\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\\\/#organizationLogo\"},\"legalName\":\"Joscur Limited\",\"sameAs\":[\"https:\\\/\\\/www.instagram.com\\\/one_peptides\\\/\"],\"contactPoint\":{\"@type\":\"ContactPoint\",\"email\":\"contact@one-peptides.com\",\"contactType\":\"customer service\"},\"parentOrganization\":{\"@type\":\"Organization\",\"name\":\"Joscur Limited\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/team-bartosz-bartczak\\\/#person\",\"url\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/team-bartosz-bartczak\\\/\",\"name\":\"Bartosz Bartczak\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/18c5ebea790bc7a8bd4088066983b1a92e5db957aa4e5888766fe20b92c9cfe6?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"Bartosz Bartczak\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/team-aneta-kropicka\\\/#person\",\"name\":\"Aneta Kropicka\",\"honorificPrefix\":\"M.Pharm.\",\"url\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/team-aneta-kropicka\\\/\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\\\/#webpage\",\"url\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\\\/\",\"name\":\"CJC-1295 DAC vs. Non-DAC \\u2014 Differences | One Peptides\",\"description\":\"CJC-1295 with DAC (half-life ~6\\u20138 days) vs. without DAC \\\/ Mod GRF 1-29 (~30 min). Differences between peptides variants, mechanism of action. Research-use-only.\",\"inLanguage\":\"de-DE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/team-bartosz-bartczak\\\/#person\"},\"creator\":{\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/team-bartosz-bartczak\\\/#person\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/one-peptides.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cjc-1295.webp\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\\\/#mainImage\",\"width\":1536,\"height\":1024,\"caption\":\"CJC-1295 with DAC vs. without DAC\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\\\/#mainImage\"},\"datePublished\":\"2026-06-21T07:33:16+00:00\",\"dateModified\":\"2026-10-03T14:55:57+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/\",\"name\":\"One-Peptides\",\"inLanguage\":\"de-DE\",\"publisher\":{\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO Pro -->\r\n\t\t<title>CJC-1295 DAC vs. Non-DAC \u2014 Differences | One Peptides<\/title>\n\n","aioseo_head_json":{"title":"CJC-1295 DAC vs. Non-DAC \u2014 Differences | One Peptides","description":"CJC-1295 with DAC (half-life ~6\u20138 days) vs. without DAC \/ Mod GRF 1-29 (~30 min). Differences between peptides variants, mechanism of action. Research-use-only.","canonical_url":"https:\/\/one-peptides.com\/de\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/one-peptides.com\/de\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\/#blogposting","name":"CJC-1295 DAC vs. Non-DAC \u2014 Differences | One Peptides","headline":"CJC-1295 (DAC and No DAC) \u2014 the difference between the variants and what the research says","author":{"@id":"https:\/\/one-peptides.com\/de\/team-bartosz-bartczak\/#person"},"publisher":{"@id":"https:\/\/one-peptides.com\/de\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/one-peptides.com\/wp-content\/uploads\/2026\/06\/cjc-1295.webp","width":1536,"height":1024,"caption":"CJC-1295 with DAC vs. without DAC"},"datePublished":"2026-06-21T07:33:16+00:00","dateModified":"2026-10-03T14:55:57+00:00","inLanguage":"de-DE","mainEntityOfPage":{"@id":"https:\/\/one-peptides.com\/de\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\/#webpage"},"isPartOf":{"@id":"https:\/\/one-peptides.com\/de\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\/#webpage"},"articleSection":"Regeneration &amp; research peptides","wordCount":2145,"reviewedBy":{"@id":"https:\/\/one-peptides.com\/de\/team-aneta-kropicka\/#person"}},{"@type":"BreadcrumbList","@id":"https:\/\/one-peptides.com\/de\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/one-peptides.com\/de\/#listItem","position":1,"name":"Home","item":"https:\/\/one-peptides.com\/de\/","nextItem":{"@type":"ListItem","@id":"https:\/\/one-peptides.com\/de\/category\/regeneration\/#listItem","name":"Regeneration &amp; research peptides"}},{"@type":"ListItem","@id":"https:\/\/one-peptides.com\/de\/category\/regeneration\/#listItem","position":2,"name":"Regeneration &amp; research peptides","item":"https:\/\/one-peptides.com\/de\/category\/regeneration\/","nextItem":{"@type":"ListItem","@id":"https:\/\/one-peptides.com\/de\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\/#listItem","name":"CJC-1295 (DAC and No DAC) \u2014 the difference between the variants and what the research says"},"previousItem":{"@type":"ListItem","@id":"https:\/\/one-peptides.com\/de\/#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/one-peptides.com\/de\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\/#listItem","position":3,"name":"CJC-1295 (DAC and No DAC) \u2014 the difference between the variants and what the research says","previousItem":{"@type":"ListItem","@id":"https:\/\/one-peptides.com\/de\/category\/regeneration\/#listItem","name":"Regeneration &amp; research peptides"}}]},{"@type":"Organization","@id":"https:\/\/one-peptides.com\/de\/#organization","name":"One-Peptides","url":"https:\/\/one-peptides.com\/de\/","logo":{"@type":"ImageObject","url":"https:\/\/one-peptides.com\/wp-content\/uploads\/2024\/09\/cropped-Image-1-e1751599136894.png","@id":"https:\/\/one-peptides.com\/de\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\/#organizationLogo","width":291,"height":113},"image":{"@id":"https:\/\/one-peptides.com\/de\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\/#organizationLogo"},"legalName":"Joscur Limited","sameAs":["https:\/\/www.instagram.com\/one_peptides\/"],"contactPoint":{"@type":"ContactPoint","email":"contact@one-peptides.com","contactType":"customer service"},"parentOrganization":{"@type":"Organization","name":"Joscur Limited"}},{"@type":"Person","@id":"https:\/\/one-peptides.com\/de\/team-bartosz-bartczak\/#person","url":"https:\/\/one-peptides.com\/de\/team-bartosz-bartczak\/","name":"Bartosz Bartczak","image":{"@type":"ImageObject","@id":"https:\/\/one-peptides.com\/de\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/18c5ebea790bc7a8bd4088066983b1a92e5db957aa4e5888766fe20b92c9cfe6?s=96&d=mm&r=g","width":96,"height":96,"caption":"Bartosz Bartczak"}},{"@type":"Person","@id":"https:\/\/one-peptides.com\/de\/team-aneta-kropicka\/#person","name":"Aneta Kropicka","honorificPrefix":"M.Pharm.","url":"https:\/\/one-peptides.com\/de\/team-aneta-kropicka\/"},{"@type":"WebPage","@id":"https:\/\/one-peptides.com\/de\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\/#webpage","url":"https:\/\/one-peptides.com\/de\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\/","name":"CJC-1295 DAC vs. Non-DAC \u2014 Differences | One Peptides","description":"CJC-1295 with DAC (half-life ~6\u20138 days) vs. without DAC \/ Mod GRF 1-29 (~30 min). Differences between peptides variants, mechanism of action. Research-use-only.","inLanguage":"de-DE","isPartOf":{"@id":"https:\/\/one-peptides.com\/de\/#website"},"breadcrumb":{"@id":"https:\/\/one-peptides.com\/de\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\/#breadcrumblist"},"author":{"@id":"https:\/\/one-peptides.com\/de\/team-bartosz-bartczak\/#person"},"creator":{"@id":"https:\/\/one-peptides.com\/de\/team-bartosz-bartczak\/#person"},"image":{"@type":"ImageObject","url":"https:\/\/one-peptides.com\/wp-content\/uploads\/2026\/06\/cjc-1295.webp","@id":"https:\/\/one-peptides.com\/de\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\/#mainImage","width":1536,"height":1024,"caption":"CJC-1295 with DAC vs. without DAC"},"primaryImageOfPage":{"@id":"https:\/\/one-peptides.com\/de\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\/#mainImage"},"datePublished":"2026-06-21T07:33:16+00:00","dateModified":"2026-10-03T14:55:57+00:00"},{"@type":"WebSite","@id":"https:\/\/one-peptides.com\/de\/#website","url":"https:\/\/one-peptides.com\/de\/","name":"One-Peptides","inLanguage":"de-DE","publisher":{"@id":"https:\/\/one-peptides.com\/de\/#organization"}}]},"og:locale":"de_DE","og:site_name":"One-Peptides -","og:type":"article","og:title":"CJC-1295 DAC vs. Non-DAC \u2014 Differences | One Peptides","og:description":"CJC-1295 with DAC (half-life ~6\u20138 days) vs. without DAC \/ Mod GRF 1-29 (~30 min). Differences between peptides variants, mechanism of action. Research-use-only.","og:url":"https:\/\/one-peptides.com\/de\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\/","og:image":"https:\/\/one-peptides.com\/wp-content\/uploads\/2026\/06\/cjc-1295.webp","og:image:secure_url":"https:\/\/one-peptides.com\/wp-content\/uploads\/2026\/06\/cjc-1295.webp","og:image:width":1536,"og:image:height":1024,"article:published_time":"2026-06-21T07:33:16+00:00","article:modified_time":"2026-10-03T14:55:57+00:00","twitter:card":"summary_large_image","twitter:title":"CJC-1295 DAC vs. Non-DAC \u2014 Differences | One Peptides","twitter:description":"CJC-1295 with DAC (half-life ~6\u20138 days) vs. without DAC \/ Mod GRF 1-29 (~30 min). Differences between peptides variants, mechanism of action. Research-use-only.","twitter:image":"https:\/\/one-peptides.com\/wp-content\/uploads\/2026\/06\/cjc-1295.webp"},"aioseo_meta_data":{"post_id":"2076","title":"CJC-1295 DAC vs. Non-DAC \u2014 Differences | One Peptides","description":"CJC-1295 with DAC (half-life ~6\u20138 days) vs. without DAC \/ Mod GRF 1-29 (~30 min). Differences between peptides variants, mechanism of action. Research-use-only.","keywords":null,"keyphrases":{"focus":{"keyphrase":"CJC-1295","score":82},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"BlogPosting","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"seo_analyzer_scan_date":"2026-10-03 14:57:11","breadcrumb_settings":null,"limit_modified_date":false,"open_ai":null,"ai":{"faqs":[],"keyPoints":[],"schemas":[],"titles":[],"descriptions":[],"socialPosts":{"email":{"subject":"","preview":"","content":""},"linkedin":[],"twitter":[],"facebook":[],"instagram":[]}},"created":"2026-06-21 07:26:12","updated":"2026-10-03 15:57:00","focus_keyword":"CJC-1295","additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t<a href=\"https:\/\/one-peptides.com\/de\/\" title=\"Home\">Home<\/a>\n<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t<a href=\"https:\/\/one-peptides.com\/de\/category\/regeneration\/\" title=\"Regeneration &amp; research peptides\">Regeneration &amp; research peptides<\/a>\n<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\tCJC-1295 (DAC and No DAC) \u2014 the difference between the variants and what the research says\n<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/one-peptides.com\/de\/"},{"label":"Regeneration &amp; research peptides","link":"https:\/\/one-peptides.com\/de\/category\/regeneration\/"},{"label":"CJC-1295 (DAC and No DAC) \u2014 the difference between the variants and what the research says","link":"https:\/\/one-peptides.com\/de\/cjc-1295-dac-and-no-dac-the-difference-between-the-variants-and-what-the-research-says\/"}],"_links":{"self":[{"href":"https:\/\/one-peptides.com\/de\/wp-json\/wp\/v2\/posts\/2076","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/one-peptides.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/one-peptides.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/one-peptides.com\/de\/wp-json\/wp\/v2\/users\/31"}],"replies":[{"embeddable":true,"href":"https:\/\/one-peptides.com\/de\/wp-json\/wp\/v2\/comments?post=2076"}],"version-history":[{"count":10,"href":"https:\/\/one-peptides.com\/de\/wp-json\/wp\/v2\/posts\/2076\/revisions"}],"predecessor-version":[{"id":2840,"href":"https:\/\/one-peptides.com\/de\/wp-json\/wp\/v2\/posts\/2076\/revisions\/2840"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/one-peptides.com\/de\/wp-json\/wp\/v2\/media\/2077"}],"wp:attachment":[{"href":"https:\/\/one-peptides.com\/de\/wp-json\/wp\/v2\/media?parent=2076"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/one-peptides.com\/de\/wp-json\/wp\/v2\/categories?post=2076"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/one-peptides.com\/de\/wp-json\/wp\/v2\/tags?post=2076"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}